Total Payments
$11,248
2024 Payments
$556.47
Companies
16
Transactions
79
Medicare Patients
14,505
Medicare Billing
$7.6M
Payment Breakdown by Category
Consulting$5,495 (48.9%)
Food & Beverage$3,272 (29.1%)
Other$2,210 (19.6%)
Travel$270.84 (2.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,495 | 2 | 48.9% |
| Food and Beverage | $3,272 | 61 | 29.1% |
| Current or prospective ownership or investment interest | $2,210 | 7 | 19.6% |
| Travel and Lodging | $270.84 | 1 | 2.4% |
| Unspecified | $0 | 8 | 0.0% |
Payments by Type
General
$11,248
71 transactions
Ownership
$0
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Hexal AG | $5,286 | 6 | $0 (2017) |
| US Retina LLC | $2,210 | 15 | $0 (2024) |
| Carl Zeiss Meditec, Inc. | $1,845 | 3 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $433.66 | 9 | $0 (2024) |
| ABBVIE INC. | $311.90 | 15 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $306.83 | 3 | $0 (2019) |
| Apellis Pharmaceuticals, Inc. | $173.99 | 5 | $0 (2024) |
| Genentech USA, Inc. | $152.99 | 7 | $0 (2024) |
| Alimera Sciences, Inc. | $126.31 | 5 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $119.97 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $556.47 | 20 | Regeneron Healthcare Solutions, Inc. ($181.13) |
| 2023 | $613.44 | 20 | ABBVIE INC. ($132.57) |
| 2022 | $1,157 | 14 | US Retina LLC ($931.96) |
| 2021 | $523.81 | 5 | US Retina LLC ($480.94) |
| 2020 | $1,999 | 4 | Carl Zeiss Meditec, Inc. ($1,625) |
| 2019 | $615.87 | 4 | US Retina LLC ($379.00) |
| 2018 | $390.23 | 4 | Carl Zeiss Meditec, Inc. ($163.13) |
| 2017 | $5,392 | 8 | Hexal AG ($5,286) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $27.24 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.91 | General |
| Category: EYE CARE | ||||||
| 10/02/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: EYE CARE | ||||||
| 09/23/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.68 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/22/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $28.16 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 08/18/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $35.02 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 06/28/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $17.84 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 06/13/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: Immunology and Ophthalmology | ||||||
| 06/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: EYE CARE | ||||||
| 03/20/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 03/19/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $34.42 | General |
| Category: Ophthalmology | ||||||
| 03/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $19.60 | General |
| Category: EYE CARE | ||||||
| 03/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $17.31 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/16/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $34.66 | General |
| Category: Ophthalmology | ||||||
| 02/15/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $23.25 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 01/25/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $21.52 | General |
| Category: EYE CARE | ||||||
| 01/18/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $110.25 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/08/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $22.27 | General |
| Category: Immunology and Ophthalmology | ||||||
| 2024 | US Retina LLC | — | — | — | $0.00 | Ownership |
| 12/20/2023 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | Cash or cash equivalent | $34.94 | General |
| 12/11/2023 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $24.12 | General |
| Category: EYE CARE | ||||||
| 12/06/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $30.49 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/29/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Food and Beverage | In-kind items and services | $119.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/16/2023 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: Immunology and Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 3,452 | 17,602 | $3.7M | $1.8M |
| 2022 | 19 | 3,477 | 9,434 | $3.8M | $1.8M |
| 2021 | 22 | 4,111 | 11,015 | $3.9M | $2.1M |
| 2020 | 22 | 3,465 | 10,384 | $4.3M | $2.0M |
Total Patients
14,505
Total Services
48,435
Medicare Billing
$7.6M
Procedure Codes
84
All Medicare Procedures & Services
84 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 143 | 1,521 | $2.1M | $1.0M | 50.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 28 | 8,645 | $343,200 | $233,457 | 68.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 234 | 1,362 | $436,200 | $122,089 | 28.0% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 12 | 402 | $168,000 | $72,281 | 43.0% |
| 92134 | Imaging of retina | Office | 2023 | 926 | 2,433 | $194,640 | $71,552 | 36.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 382 | 867 | $95,370 | $59,086 | 62.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 413 | 587 | $91,572 | $52,423 | 57.2% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 401 | 410 | $75,850 | $35,411 | 46.7% |
| J3590 | Unclassified biologics | Office | 2023 | 108 | 430 | $101,910 | $31,155 | 30.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 134 | 134 | $30,150 | $16,684 | 55.3% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 13 | 13 | $29,250 | $11,940 | 40.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 84 | 86 | $21,500 | $9,254 | 43.0% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 408 | 467 | $16,345 | $8,660 | 53.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 19 | 22 | $17,600 | $4,296 | 24.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 51 | 64 | $8,000 | $2,241 | 28.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $3,360 | $1,762 | 52.5% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 13 | 13 | $2,860 | $1,407 | 49.2% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 22 | 25 | $3,125 | $1,143 | 36.6% |
| 92250 | Photography of the retina | Office | 2023 | 24 | 27 | $2,700 | $749.03 | 27.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 13 | $910.00 | $558.84 | 61.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 13 | 69 | $266.00 | $55.60 | 20.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 127 | 1,686 | $2.3M | $1.2M | 51.8% |
| 67028 | Injection of drug into eye | Office | 2022 | 261 | 1,537 | $485,100 | $137,593 | 28.4% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2022 | 15 | 495 | $207,900 | $110,145 | 53.0% |
| 92134 | Imaging of retina | Office | 2022 | 904 | 2,462 | $196,960 | $73,429 | 37.3% |
About Dr. Michael Ober, MD
Dr. Michael Ober, MD is a Retina Specialist healthcare provider based in Southfield, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003976416.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ober, MD has received a total of $11,248 in payments from pharmaceutical and medical device companies, with $556.47 received in 2024. These payments were reported across 79 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($5,495).
As a Medicare-enrolled provider, Ober has provided services to 14,505 Medicare beneficiaries, totaling 48,435 services with total Medicare billing of $7.6M. Data is available for 4 years (2020–2023), covering 84 distinct procedure/service records.
Ad
Practice Information
- Specialty Retina Specialist
- Other Specialties Ophthalmology
- Location Southfield, MI
- Active Since 12/08/2006
- Last Updated 03/09/2021
- Taxonomy Code 207WX0107X
- Entity Type Individual
- NPI Number 1003976416
Products in Payments
- OZURDEX (Drug) $334.76
- EYLEA (Biological) $311.23
- EYLEA HD (Biological) $242.40
- YUTIQ (Drug) $173.56
- CIRRUS HD-OCT (Device) $163.13
- Vabysmo (Drug) $109.29
- DUREZOL (Drug) $105.89
- ARTEVO 800 (Device) $86.58
- Constellation (Device) $85.01
- Syfovre (Drug) $69.08
- XIPERE (Drug) $55.05
- DEXYCU (Drug) $20.76
- VISUDYNE (Drug) $20.01
- VABYSMO (Drug) $17.98
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.